

## Krizus, Astrid

---

**From:** Hird, Mac  
**Sent:** Thursday, October 22, 2020 3:30 PM  
**To:** Krizus, Astrid; Hage-Moussa, Vanessa; fitz-morris, James (SPAC/PSPC); Theis, Rick  
**Subject:** RE: BD contract for rapid test

And Astrid, just to reconcile a different chain that I'm on with PSCP, re: Medicago we can drop in the number of doses, in red below.

To begin with, we're providing up to \$173 million for Quebec City-based Medicago, to advance their vaccine candidate and create a production facility in Quebec City. Our government also has an agreement with the company to supply up to 76 million doses of their vaccine.

---

**From:** Krizus, Astrid <Astrid.Krizus@pmo-cpm.gc.ca>  
**Sent:** Thursday, October 22, 2020 2:56 PM  
**To:** Hage-Moussa, Vanessa <Vanessa.Hage-Moussa@pmo-cpm.gc.ca>; fitz-morris, James (SPAC/PSPC) <james.fitz-morris@canada.ca>; Theis, Rick <Rick.Theis@pmo-cpm.gc.ca>; Hird, Mac <Mac.Hird@pmo-cpm.gc.ca>  
**Subject:** RE: BD contract for rapid test

James, does this work for you for the PM mention of BD in tomorrow's speech?

*To ensure that we have as many resources available as possible, Health Canada has also authorized another rapid test, the BD Veritor.*

*This is a handheld device that can process a test every 15 minutes.*

*Canada has a contract for 7.6 million of these tests, including millions by the end of this year.*

---

**From:** Hage-Moussa, Vanessa <Vanessa.Hage-Moussa@pmo-cpm.gc.ca>  
**Sent:** Thursday, October 22, 2020 2:53 PM  
**To:** fitz-morris, James (SPAC/PSPC) <james.fitz-morris@canada.ca>; Theis, Rick <Rick.Theis@pmo-cpm.gc.ca>; Hird, Mac <Mac.Hird@pmo-cpm.gc.ca>  
**Cc:** Krizus, Astrid <Astrid.Krizus@pmo-cpm.gc.ca>  
**Subject:** RE: BD contract for rapid test

Thanks James – adding Astrid

---

**From:** fitz-morris, James (SPAC/PSPC) <james.fitz-morris@canada.ca>  
**Sent:** Thursday, October 22, 2020 2:19 PM  
**To:** Hage-Moussa, Vanessa <Vanessa.Hage-Moussa@pmo-cpm.gc.ca>; Theis, Rick <Rick.Theis@pmo-cpm.gc.ca>; Hird, Mac <Mac.Hird@pmo-cpm.gc.ca>  
**Subject:** BD contract for rapid test

Hello,

Here is the thumbnail of the contract with BD:

The initial order for 600 analyzers (to be delivered by the end of 2020) and 7.6M tests (2.1M to be delivered by the end of 2020, the rest – in Q1 2021) is for \$244.9M. The option for an additional 1,572 analyzers (to be delivered by the end of Q1 2020) is worth \$0.7M, for a maximum contract value of \$245.6M.

**Key considerations:**

- This testing solution is similar to Cepheid's GenExpert and Abbott's ID Now in that it uses a **small point of care analyzer**; however, it relies on **antigen** technology, like the Abbott Panbio test. It delivers a result in 15 minutes.
- The contract is in response to a PHAC requisition and the **test received HC regulatory authorization on October 10**.
- The **price of the consumables** for each incremental test is **\$28** which is higher than the unit cost of Panbio (\$6.55) but lower than GenExpert (\$45-50) and ID Now (\$35).
- The expected **sensitivity of this test is 84%** which exceeds the minimum threshold of 80% set by Health Canada for antigen tests (the specificity is 100%). However, this is still significantly lower than the sensitivity of the other tests that we have procured so far (all are above 93%). It means that if a person is negative, it is highly unlikely that the test will generate a false positive; yet, for every 100 COVID-positive people tested, 16 would get false negatives results. This could be managed if the test is deployed for testing lower risk groups and Minister Hajdu's office have confirmed that Health Canada will issue deployment guidelines before they distribute any tests to PTs.
- HC has investigated the recent **reports out of Nevada** that the tests produce too many false positives and confirmed that the false positive rate is within the expected margin of error. In addition, the NML is performing further evaluations and no tests will be shipped before that study is completed. PSPC and BD have agreed that in case the NML decides not to accept the test following their study, the contract will be terminated by mutual consent.

James Fitz-Morris

Directeur des communications / Director of Communications

Cabinet de la ministre des Services publics et de l'Approvisionnement / Office of the Minister of Public Services and Procurement

[james.fitz-morris@canada.ca](mailto:james.fitz-morris@canada.ca)

Cell : 613-698-2387